Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SMMT Summit Therapeutics PLC

交易中 02-25 13:15:40 EST

15.88

-0.24

-1.49%

最高16.51	最低15.64	成交量56.36万
今开16.20	昨收16.12	日振幅5.40%
总市值123.13亿	流通市值20.49亿	总股本7.75亿
成交额901.94万	换手率0.44%	流通股本1.29亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SMMT","market":"US","secType":"STK","nameCN":"Summit Therapeutics PLC","latestPrice":15.88,"timestamp":1772043333204,"preClose":16.12,"halted":0,"volume":563584,"delay":0,"changeRate":-0.014888337468982642,"floatShares":129000000,"shares":775372700,"eps":-1.44,"marketStatus":"交易中","change":-0.24,"latestTime":"02-25 13:15:40 EST","open":16.2,"high":16.51,"low":15.64,"amount":9019383.046912,"amplitude":0.05397,"askPrice":15.88,"askSize":15,"bidPrice":15.86,"bidSize":220,"shortable":3,"etf":0,"ttmEps":-1.44,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772053200000},"marketStatusCode":2,"adr":1,"adrRate":5,"listingDate":1425531600000,"exchange":"NASDAQ","adjPreClose":16.12,"preHourTrading":{"tag":"盘前","latestPrice":16.2,"preClose":16.12,"latestTime":"09:22 EST","volume":737,"amount":11909.129936,"timestamp":1772029326988,"change":0.08,"changeRate":0.004963,"amplitude":0.019231},"postHourTrading":{"tag":"盘后","latestPrice":16.1,"preClose":16.12,"latestTime":"19:54 EST","volume":73854,"amount":1190413.11,"timestamp":1771980867579,"change":-0.02,"changeRate":-0.001241,"amplitude":0.01799},"volumeRatio":0.492022,"impliedVol":0.6948,"impliedVolPercentile":0.1275},"requestUrl":"/m/hq/s/SMMT","defaultTab":"news","newsList":[{"id":"1107476933","title":"Summit Therapeutics盘前大涨5.5% 美国FDA受理其Ivonescimab上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1107476933","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107476933?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:36","pubTimestamp":1769690215,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC股价在盘前交易中强势攀升5.5%，此前美国食品药品监督管理局正式受理了该公司提交的双特异性抗体药物Ivonescimab的新药上市申请。\n这一关键监管里程碑的达成，为这款创新肿瘤免疫疗法的审评进程铺平了道路，同时也显著提振了市场投资者对该公司未来发展前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"gpt_icon":0},{"id":"1142715038","title":"Summit Therapeutics宣布美国FDA受理Ivonescimab联合化疗治疗EGFR突变非小细胞肺癌患者TKI治疗后生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1142715038","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142715038?lang=zh_cn&edition=full","pubTime":"2026-01-29 20:31","pubTimestamp":1769689877,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC宣布，美国食品药品监督管理局（FDA）已正式受理其提交的生物制品许可申请（BLA）。该申请旨在寻求批准Ivonescimab与化疗联合，用于治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者，这些患者此前已接受过酪氨酸激酶抑制剂（TKI）治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4139","SMMT"],"gpt_icon":0},{"id":"1190691688","title":"Summit Therapeutics：双方保留各自产品权益，协议具有双向非排他性","url":"https://stock-news.laohu8.com/highlight/detail?id=1190691688","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190691688?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:18","pubTimestamp":1768216682,"startTime":"0","endTime":"0","summary":"根据最新合作协议条款，Summit Therapeutics PLC（以下简称Summit）与其合作伙伴将保持对各自研发产品的完整所有权。该协议采用双向非排他性模式，意味着双方均可独立开展与其他实体的合作，同时保留对自有知识产权的绝对控制权。\n这一安排既保障了双方在特定领域的自主运营空间，又为未来潜在的战略协同留下弹性。非排他性条款尤其凸显了合作框架的灵活性，允许各方在遵守协议基础上自由探索多元化的商业机会。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203347892.USD","LU0109981661.USD","GSK.UK","LU1064927863.SGD","LU1202635105.USD","LU0211331839.USD","LU0161305163.EUR","LU0545562505.USD","LU0575583348.USD","LU0203345920.USD","LU0289739699.SGD","BK4139","IE0034235071.USD","LU0971552673.USD","LU0225771236.USD","LU1302929846.USD","LU1481600234.SGD","LU1035777561.USD","LU1481599808.USD","LU0985481810.HKD","LU2488822045.USD","IE00BWDBJ516.SGD","LU0306806265.USD","LU0225284248.USD","LU1046248800.SGD","LU0058720904.USD","LU0321505439.SGD","LU0971552830.HKD","LU0306807586.USD","LU1015430645.USD","LU1670756490.USD","LU1400636574.HKD","LU0321505868.SGD","LU1228905540.USD","LU1487256676.USD","LU1983299246.USD","IE00B3T34201.USD","BK5011","LU1400636491.USD","LU1309081286.SGD","LU1228905037.USD","LU1400636657.SGD","SMMT","LU1645745479.HKD","LU1098665638.USD","IE00BQJZX424.USD"],"gpt_icon":0},{"id":"2601485265","title":"50亿英镑折扣撬动市场！英国2025年新车销量重回200万辆 中国品牌加速崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2601485265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601485265?lang=zh_cn&edition=full","pubTime":"2026-01-06 10:25","pubTimestamp":1767666309,"startTime":"0","endTime":"0","summary":"英国汽车制造商和贸易商协会周二公布的数据显示，2025年新车注册量增长3.5%，达到202万辆。中国汽车日益增长的受欢迎度助力英国汽车销量重回200万辆以上水平，其更亲民的价格吸引了消费者。英国对中国品牌尤其具有吸引力，因为它没有效仿欧盟对中国制造的电动汽车加征关税。这家英国最大的汽车制造商被迫停产近六周，促使政府出面提供15亿英镑的紧急贷款担保，以帮助陷入困境的供应商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389041.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SMMT","LU2488822045.USD","BK4139"],"gpt_icon":0},{"id":"1158928922","title":"Summit Therapeutics申请最多2670万股普通股的配售 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1158928922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158928922?lang=zh_cn&edition=full","pubTime":"2025-10-30 05:14","pubTimestamp":1761772463,"startTime":"0","endTime":"0","summary":"Summit Therapeutics申请最多2670万股普通股的配售，售出股东将在SEC备案中进行披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"gpt_icon":0},{"id":"2578752044","title":"中外制药获得部分IgA肾病药物权利，峰会治疗公司筹集5亿美元Chugai Pharmaceutical Gains Partial Rights to IgA Nephropathy Drug as Summit Therapeutics Raises $500 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2578752044","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578752044?lang=zh_cn&edition=full","pubTime":"2025-10-24 23:08","pubTimestamp":1761318480,"startTime":"0","endTime":"0","summary":"by Mark Chiang马克·蒋Share To分享到Chugai Pharmaceutical has secured partial rights to a drug used in the treatment of IgA nephropathy, a chronic kidney disease. The acquisition involves a marketed therapy aimed at addressing this condition. Meanwhile, the Institute for Clinical and Economic Review  released findings suggesting that Americans are frequently paying higher-than-necessary prices for medications.中外制药获得了用于治疗IgA肾病的药物的部分权利。Additionally, Summit Therapeutics announced it has raised $500 million in funding..此外，Summit Therapeutics宣布已筹集5亿美元资金。The developments highlight ongoing activity within the pharmaceutical sector. Chugai’s move reflects continued interest in therapies targeting renal diseases, while ICER’s report underscores concerns about drug pricing trends in the U.S. Summit’s funding round marks a significant financial milestone for the company as it seeks to advance its pipeline of treatments.这些进展突显了制药行业内的持续活跃。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102423101194dbd593&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025102423101194dbd593&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","SMMT","LU2488822045.USD","BK4007","BK4139"],"gpt_icon":0},{"id":"2576865028","title":"Summit Thera三季度每股亏损0.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576865028","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576865028?lang=zh_cn&edition=full","pubTime":"2025-10-20 23:29","pubTimestamp":1760974140,"startTime":"0","endTime":"0","summary":"美股周一早盘，生物制药企业Summit Therapeutics（SMMT）股价下跌4.9%，此前该公司报告第三季度每股亏损0.13美元，未达预期。尽管盈利不及预期，公司现金储备依然雄厚，支持其持续的战略计划。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-10-20/doc-infuqfta5063279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SINA","BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"1182230580","title":"Summit Therapeutics股票因未披露肺癌试验整体生存数据和第三季度业绩下跌7.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182230580","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182230580?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:34","pubTimestamp":1760967262,"startTime":"0","endTime":"0","summary":"Summit Therapeutics股票因未披露肺癌试验整体生存数据和第三季度业绩下跌7.7%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"1136397665","title":"异动解读 | Summit Therapeutics盘前大跌5.67%，新临床试验计划和财报引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1136397665","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136397665?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:10","pubTimestamp":1760958633,"startTime":"0","endTime":"0","summary":"Summit Therapeutics PLC今日盘前大跌5.67%，引发市场关注。该公司今日早间发布了两则重要公告，可能是导致股价下跌的原因。首先，Summit Therapeutics宣布将启动一系列新的III期Harmoni-Gi3临床试验，但详细信息要到2026年第一季度才会公布。这一消息可能引发了投资者对公司研发进展的担忧。其次，公司同时发布了2025年第三季度及截至9月30日的九个月财务结果和运营进展报告。市场似乎对Summit Therapeutics的短期前景持谨慎态度，这反映在盘前的显著跌幅上。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SMMT"],"gpt_icon":0},{"id":"1110374669","title":"Summit Therapeutics：将启动一系列新的III期Harmoni-Gi3临床试验，详细信息将于2026年第一季度发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1110374669","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110374669?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:49","pubTimestamp":1760957349,"startTime":"0","endTime":"0","summary":"Summit Therapeutics：将启动一系列新的III期Harmoni-Gi3临床试验，详细信息将于2026年第一季度发布","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMMT","LU2488822045.USD","BK4139"],"gpt_icon":0},{"id":"1123453947","title":"Summit Therapeutics 发布2025年第三季度及截至9月30日的九个月财务结果和运营进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1123453947","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123453947?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:46","pubTimestamp":1760957181,"startTime":"0","endTime":"0","summary":"Summit Therapeutics 发布2025年第三季度及截至9月30日的九个月财务结果和运营进展","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SMMT","LU2488822045.USD"],"gpt_icon":0},{"id":"1194256836","title":"伊沃赛单抗与化疗相较于替雷利珠单抗及化疗在中国Harmoni-6研究中降低鳞状非小细胞肺癌患者疾病进展或死亡风险40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194256836","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194256836?lang=zh_cn&edition=full","pubTime":"2025-10-19 22:31","pubTimestamp":1760884305,"startTime":"0","endTime":"0","summary":"伊沃赛单抗与化疗相较于替雷利珠单抗（PD-1抑制剂）加化疗，在中国进行的Harmoni-6研究中，在一线治疗鳞状非小细胞肺癌患者时，降低了疾病进展或死亡的风险40%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"1124798722","title":"Summit Therapeutics扩展Ivonescimab全球III期开发计划，启动1L结直肠癌的Harmoni-Gi3研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1124798722","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124798722?lang=zh_cn&edition=full","pubTime":"2025-10-17 19:01","pubTimestamp":1760698900,"startTime":"0","endTime":"0","summary":"Summit Therapeutics扩展Ivonescimab全球III期开发计划，启动1L结直肠癌的Harmoni-Gi3研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK4139","SMMT"],"gpt_icon":0},{"id":"2564589614","title":"坐享康方生物(09926)创新药红利 合作伙伴Summit(SMMT.US)获H.C.Wainwright上调目标价至50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564589614","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564589614?lang=zh_cn&edition=full","pubTime":"2025-09-01 14:12","pubTimestamp":1756707123,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，H.C. Wainwright发 表研报，将Summit Therapeutics Inc.目标价从44美元上调至50美元，并维持“买入”评级。报告同时强调，当前正是布局Summit的良机，因其作为康方生物在美国市场的合作伙伴，具有独特优势。据了解，Summit是一家生物制药企业，致力于研发和商业化针对严重未满足医疗需求的创新疗法，其产品注重患者、家属、医生及社会效益，旨在延长寿命并提升生活质量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"c0b61b62afdaf0b7c4308a9678a42926","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1339833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","SMMT","09926"],"gpt_icon":0},{"id":"2518436278","title":"Summit Therapeutics Inc.盘中异动 股价大跌5.91%报16.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518436278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518436278?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:31","pubTimestamp":1741613469,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时31分，Summit Therapeutics Inc.股票出现异动，股价急速跳水5.91%。截至发稿，该股报16.73美元/股，成交量9.1706万股，换手率0.01%，振幅0.81%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.59%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310998a29c8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021310998a29c8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU2488822045.USD","BK4139","SMMT"],"gpt_icon":0},{"id":"2517516510","title":"Summit Therapeutics Inc.盘中异动 早盘股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517516510","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517516510?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:34","pubTimestamp":1741271643,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时34分，Summit Therapeutics Inc.股票出现波动，股价急速下跌5.06%。截至发稿，该股报18.56美元/股，成交量5.6688万股，换手率0.01%，振幅2.05%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体跌幅为0.64%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223403abeb7870&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223403abeb7870&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","LU2488822045.USD","SMMT"],"gpt_icon":0},{"id":"2516650980","title":"Summit Therapeutics Inc.盘中异动 急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516650980","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516650980?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:36","pubTimestamp":1741030563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时36分，Summit Therapeutics Inc.股票出现异动，股价快速下跌5.12%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4550.84%、206.83%、181.58%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040336039637f047&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503040336039637f047&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SMMT","BK4139","LENZ","LU2488822045.USD"],"gpt_icon":0},{"id":"2514376555","title":"Summit Therapeutics Inc.盘中异动 早盘大幅拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514376555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514376555?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:26","pubTimestamp":1740756399,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时26分，Summit Therapeutics Inc.股票出现异动，股价急速拉升5.08%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Bioxcel Therapeutics, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Puma Biotechnology Inc涨幅较大，Bioxcel Therapeutics, Inc.、Enveric Biosciences, Inc.、Virpax Pharmaceuticals, Inc.较为活跃，换手率分别为1430.83%、405.61%、337.95%，振幅较大的相关个股有Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 、Bioxcel Therapeutics, Inc.，振幅分别为46.60%、43.37%、38.73%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228232639a2580f75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228232639a2580f75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SMMT","LU2488822045.USD","LENZ"],"gpt_icon":0},{"id":"2514238400","title":"Summit Therapeutics Inc.2024财年实现净利润-2.21亿美元，同比增加64.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514238400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514238400?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:01","pubTimestamp":1740672061,"startTime":"0","endTime":"0","summary":"2月28日，Summit Therapeutics Inc.公布财报，公告显示公司2024财年净利润为-2.21亿美元，同比增加64.07%；其中营业收入为0.00美元，每股基本收益为-0.31美元。机构评级：截至2025年2月28日，当前有6家机构对Summit Therapeutics Inc.目标价做出预测，其中目标均价为35.33美元，其中最低目标价为30.00美元，最高目标价为44.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000106abdf84f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228000106abdf84f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SMMT","LENZ"],"gpt_icon":0},{"id":"2514867183","title":"Summit Therapeutics Inc.盘中异动 大幅上涨5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514867183","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514867183?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:32","pubTimestamp":1740666751,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时32分，Summit Therapeutics Inc.股票出现异动，股价急速拉升5.22%。截至发稿，该股报19.26美元/股，成交量5.4943万股，换手率0.01%，振幅3.20%。Summit Therapeutics Inc.股票所在的生物技术行业中，整体涨幅为0.31%。Summit Therapeutics Inc.公司简介：Summit Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化用于严重传染病的新型抗生素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223231a2567a36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227223231a2567a36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SMMT","LENZ","BK4139","LU2488822045.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.smmttx.com","stockEarnings":[{"period":"1week","weight":0.0281},{"period":"1month","weight":-0.0224},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.3399},{"period":"1year","weight":-0.1444},{"period":"ytd","weight":-0.0783}],"compareEarnings":[{"period":"1week","weight":0.0066},{"period":"1month","weight":-0.0027},{"period":"3month","weight":0.0113},{"period":"6month","weight":0.0592},{"period":"1year","weight":0.1509},{"period":"ytd","weight":0.008}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Summit Therapeutics Inc.于2013年11月22日在英格兰和威尔士注册成立，特拉华州的一家公司（“New Summit”）已成为该公司的后续发行方。该公司是一家生物制药公司，专注于发现、开发和商业化对患者、医生、护理人员和社会友好的药物疗法，旨在提高生活质量，延长潜在寿命，并解决严重的未满足的医疗需求。该公司的候选产品管线的设计目标是成为肿瘤治疗领域中对患者友好的、新时代的标准护理药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.093233},{"month":2,"riseRate":0.454545,"avgChangeRate":0.032749},{"month":3,"riseRate":0.4,"avgChangeRate":0.028993},{"month":4,"riseRate":0.454545,"avgChangeRate":0.034483},{"month":5,"riseRate":0.545455,"avgChangeRate":0.099475},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.086722},{"month":7,"riseRate":0.636364,"avgChangeRate":0.088383},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.007003},{"month":9,"riseRate":0.363636,"avgChangeRate":0.075404},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.047867},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.015842},{"month":12,"riseRate":0.454545,"avgChangeRate":0.356783}],"exchange":"NASDAQ","name":"Summit Therapeutics PLC","nameEN":"Summit Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Summit Therapeutics PLC,SMMT,Summit Therapeutics PLC股票,Summit Therapeutics PLC股票老虎,Summit Therapeutics PLC股票老虎国际,Summit Therapeutics PLC行情,Summit Therapeutics PLC股票行情,Summit Therapeutics PLC股价,Summit Therapeutics PLC股市,Summit Therapeutics PLC股票价格,Summit Therapeutics PLC股票交易,Summit Therapeutics PLC股票购买,Summit Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Summit Therapeutics PLC(SMMT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Summit Therapeutics PLC(SMMT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}